Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
Order byBest matchMost fresh
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days

Eli Lilly’s weight loss and diabetes drug tops Keytruda

Digest more
 · 10h · on MSN
Eli Lilly says weight-loss pill a candidate for speedy approval under new US program
Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's new national priority voucher, suggesting it is a strong candidate for a significantly accelerated approval review.

Continue reading

STAT · 23h
Eli Lilly’s weight loss and diabetes drug tops Keytruda as world’s best-selling medicine
Pharmaceutical Technology · 4h
Massive sales for weight loss drugs spur Eli Lilly’s Q3
1don MSN

Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar

The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and ...
19hon MSN

Eli Lilly’s obesity and diabetes treatments fuel growth and spark bidding war

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...
20h

Investor Outlook: Eli Lilly delivers another strong quarter as demand for GLP-1 drugs accelerates

Eli Lilly beats Q3 2025 estimates and raises guidance as strong GLP-1 drug sales from Mounjaro and Zepbound lift profit and ...
21h

Lilly Beats on Q3 Earnings, Ups View, Mounjaro, Zepbound Drive Sales

Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results
Feedback
  • Privacy
  • Terms